Background: Cholangiocarcinoma (CCA), consisting of intrahepatic (IHCCA), perihilar (PHCCA), and distal (DCCA) CCA, is a type of highly aggressive malignancy with a very dismal prognosis. Potential biomarkers and drug targets of CCA are urgently needed. As a new member of the Annexin (ANXA) family, the role of ANXA10 in the progression and prognosis of CCA is unknown. Methods: Potential PHCCA biomarkers were screened by transcriptome sequencing of 5 pairs of PHCCA and adjacent tissues. The clinical significance of ANXA10 was evaluated by analyzing its correlation with clinicopathological variables, and the prognostic value of ANXA10 was evaluated with univariate and multivariate analyses. The function of ANXA10 in the epithelial-mesenchymal transition (EMT), proliferation, invasion and metastasis was detected with in vitro and in vivo experiments. Moreover, we screened the key molecule in ANXA10induced CCA progression by mRNA sequencing and evaluated the correlation between PLA2G4A and ANXA10. The effect of PLA2G4A downstream signaling, including Cyclooxygenase 2, Prostaglandin E2(PGE2) and Signal transducer and activator of transcription 3(STAT3), on EMT and metastasis was further detected with in vitro and in vivo experiments. Findings: ANXA10 expression was upregulated in PHCCA and DCCA but not in IHCCA. High ANXA10 expression was significantly associated with poor tumor differentiation and prognosis. ANXA10 promoted the proliferation, migration and invasion of the PHCCA cells. PLA2G4A expression was regulated by ANXA10 and high PLA2G4A predicted poor prognosis in PHCCA and DCCA. ANXA10 facilitated EMT and promoted metastasis by upregulating PLA2G4A expression, thus increasing PGE2 levels and activating STAT3. Interpretation: ANXA10 was an independent prognostic biomarker of PHCCA and DCCA but not IHCCA. ANXA10 promoted the progression of PHCCA and facilitated metastasis by promoting the EMT process via the PLA2G4A/ PGE2/STAT3 pathway. ANXA10, PLA2G4A and their downstream molecules, such as COX2 and PGE2, may be promising drug targets of PHCCA and DCCA.
Introduction
Cholangiocarcinoma (CCA) is a malignant tumor originating from the biliary epithelium [1] . For a long time, CCA was classified into intrahepatic CCA (ICCA) and extrahepatic CCA (EHCCA) according to its anatomical location until the 7th AJCC/UICC staging system in 2007, which further categorized CCA as three subtypes: intrahepatic (ICCA), perihilar (PHCCA), and distal (DCCA) CCA [2] . This is a milestone in the study of CCA because it confirmed that each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management [3, 4] . PHCCA, also known as Klatskin's tumor, is the most common subtype and accounts for 50-70% of all CCA, while DCCA and ICCA account for approximately 20-30% and 10%, respectively [5] . Radical surgery is the main curative treatment for CCA, but ICCA, PHCCA and DCCA have completely different surgical approaches for curative treatment. Hepatectomy is the main approach for ICCA, while DCCA patients usually need to undergo local resection or pancreatoduodenectomy [6] . Surgical treatment for PHCCA is more complicated and technically challenging because of the complex, intimate and variable relationship between biliary and vascular structures at the hepatic portal [7] . Moreover, most patients with CCA have often lost their opportunity for radical surgery upon first diagnosis due to silent clinical symptoms and rapid progression [8] . Furthermore, the effects of adjuvant therapy for CCA, including chemotherapy and radiotherapy, are unsatisfactory. All of the above reasons contribute to the poor prognosis for CCA and its 5-year overall survival rate of approximately 30% after radical surgery [8] . Unfortunately, there is still no targeted drug available for CCA in the era of personalized treatment [9] . This predicament is more severe for PHCCA and DCCA because the clinical trials, preclinical drugs and studies of potential biomarkers for PHCCA and DCCA all lag far behind ICCA [10] .
The Annexin family is the largest category of eukaryotic calcium and phospholipid-binding proteins and plays important roles in various physiological processes, including cell differentiation and proliferation [11] . The Annexin A (ANXA) subclass contains 12 members in humans [12] , and the ectopic expression of the ANXA members was observed in the tumorigenesis and progression of several types of cancers, such as the up-regulation of ANXA1 in pancreatic cancer [13] . Interestingly, tumor growth and metastasis are significantly decreased in AnxA1-KO mice, indicating a critical role of ANXA1 in tumor progression [14] . However, different ANXA members play different roles in cancer progression. For example, downregulation of ANXA members was reported in certain types of tumors, such as low expression of ANXA1 and ANXA7 in prostatic cancer [15] . Moreover, the expression and function of ANXA in cancer are tissue-specific or context-specific. From the exome and transcription sequencing of PHCCA, we found that ANXA10 was upregulated in PHCCA tissues. However, as a new member of the Annexin family, the role of ANXA10 in cancer progression has rarely been investigated, and understanding its expression and function in CCA requires more experiments.
Tumor-associated chronic inflammation is a hallmark of cancer that facilitates progression to a metastatic stage. The longstanding inflammation and injury such as primary sclerosing cholangitis, bile duct calculus is a well-known risk of CCA [16, 17] . In the process of inflammation, phospholipase A2 (PLA2) is a group of key enzymes that cleave phospholipids specifically at the sn-2 position to liberate free fatty acids, mostly arachidonic acid (AA) and lysophospholipids (LPLs). PLA2 can be divided mainly into secretory PLA2s (sPLA2), cytosolic PLA2s (cPLA2), calcium-independent PLA2s (iPLA2) and other isoforms according to their location. As the main type of PLA2, cPLA2a, also known as group IVA cPLA2 (PLA2G4A), can help convert arachidonic acid to a variety of eicosanoids, mainly prostaglandin E2 (PGE2) in the presence of cyclooxygenase (COX) enzymes. In this way, cPLA2 is involved in many physiological and pathological processes, including inflammation, cell growth, invasion and metastasis. Among the ANXA family, ANXA1 is a relatively well-studied member. ANXA1 was previously reported to suppress inflammation by inhibiting the activity of cPLA2 and interfering with AA release [18, 19] . However, whether other ANXA members regulate cPLA2 activity or expression and whether cPLA2 is involved in the progression of CCA is unknown.
Here, in our study, we first screened possible biomarkers of CCA by exome and transcription sequencing of 5 pairs of PHCCA and adjacent tissues and verified the upregulation and prognostic significance of ANXA10 in PHCCA and DCCA but not in ICCA. Through in vitro and in vivo experiments, we investigated the role of ANXA10 in CCA progression. Moreover, we screened the key molecule involved in ANXA10-induced progression by mRNA sequencing and found that cPLA2a expression was regulated by ANXA10. To reveal the correlations among ANXA10, cPLA2a and CCA progression, we further studied the molecular mechanism of how cPLA2 influenced CCA progression and prognosis.
Materials and methods

Patients and follow-up
The primary cohort comprised patients who underwent surgery for ICCA (254 cases), PHCCA (374 cases) and DCCA (231 cases) at Qilu Hospital of Shandong University from 2012 to 2018. A validation cohort consisting of 91 ICCA patients, 128 PHCCA patients and 84 DCCA patients was further selected according to the following inclusion criteria: (i) patients who underwent radical resection with a clear surgical margin; (ii) patients with available formalin-fixed tumor tissues, follow-up information and complete medical records; (iii) patients with a postsurgical survival time of N1 month; and (iv) patients with no history of other malignancies. Twenty pairs of ICCA, PHCCA, and DCCA and tumor-adjacent normal tissues were collected continuously during operations on the premise of not interfering with the pathological diagnosis. The tumors were classified and staged according to the 7th AJCC/ UICC TNM classification system.
Ethics statement
Informed consent was obtained from all patients. All experiments were approved and supervised by the Ethics Committee of Qilu Hospital of Shandong University.
Research in context
Evidence before this study Cholangiocarcinoma(CCA) is a type of highly aggressive malignancy with no well-accepted target therapies. CCA can be further categorized CCA as intrahepatic (ICCA), perihilar (PHCCA), and distal (DCCA) CCA, which have a distinct epidemiology, biology, prognosis, and strategy for clinical management. The prognosis of CCA is very poor and there is still no targeted drug available for CCA in the era of personalized treatment. The clinical trials, preclinical drugs and studies of potential biomarkers of CCA lag far behind other tumors like lung cancer.
Added value of this study
In our study, we screened potential biomarkers with exome and transcriptome sequencing, and first demonstrated that ANXA10 is an independent prognostic biomarker of PHCCA and DCCA. After various in vitro and in vivo experiments, we suggested that PLA2G4A expression was regulated by ANXA10 and that it is essential for ANXA10-induced proliferation, invasion and EMT in CCA, and PGE2 generation and STAT3 activation downstream of PLA2G4A were essential in ANXA10-mediated EMT facilitation and tumor metastasis.
Implications of all the available evidence
Our results may help stratify high-risk patients with PHCCA and DCCA and guide individualized treatment for PHCCA and DCCA. Our findings suggested that ANXA10, PLA2G4A and COX-2 are potential drug targets for PHCCA and DCCA, and drugs blocking the ANXA10/PLA2G4A/PGE2 pathway such as Celecoxib are a promising therapeutic approaches for CCA treatment.
Agents and cells
Human PHCCA cell lines QBC-939 and FRH-0201 and IHCCA cell lines RBE and HCCC-9810 were all purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cell lines were maintained in DMEM (Gibco, Grand Island, New York, USA) supplemented with 10% fetal bovine serum (Gibco) and penicillin/streptomycin (HyClone) in 5% CO 2 . All cell lines were authenticated using short tandem repeat (STR) analysis, and the databases of the Chinese Academy of Sciences and American Type Culture Collection were used as references.
The inhibitors AACOCF3 (APExBIO) and celecoxib (Selleck, Houston, TX, USA) were used. All other agents without special instructions were purchased from Sigma. The information for the antibodies is detailed as follows: ANXA10(Sigma-Aldrich, St. Louis, MS, United States, C114395),Snail(Cell Signaling Technology, Danvers, MA, #3879), Vimentin(Cell Signaling Technology, #5741), E-cadherin(Cell Signaling Technology, #3195), PLA2G4A(Abcam, Cambridge, UK, ab58375), GNA13(Abcam, ab128900), STAT3(Abcam, ab68153), Phospho-Stat3-Tyr705(Cell Signaling Technolog, #9145).
Tissue microarray and IHC
Tissue microarray (TMA) was constructed using paraffin-embedded sections of tumors after hematoxylin and eosin staining to confirm the representative tumor area. Core tissues with a 1.5-mm diameter were used for TMA construction. Immunohistochemistry (IHC) was performed on the TMA slides for the detection of ANXA10 or PLA2G4A, as detailed in a previous study [20] . In brief, the slides were submerged in EDTA (pH = 9) buffer for optimal antigen retrieval. Primary ANXA10 antibody (1:500) or anti-PLA2G4A antibody (1:400) was applied and incubated with the specimens at 4°C overnight. A biotinlabeled goat anti-rabbit antibody (Zsbio, Beijing, China) was applied for 30 min at room temperature. Subsequently, the slides were incubated with conjugated horseradish peroxidase streptavidin. The peroxidase reaction was developed using a 3,3-diaminobenzidine (DAB) solution (Zsbio).
The IHC results were evaluated independently by two senior pathologists who were unaware of the clinical information. The IHC results were semi-quantitatively scored in a conventional way based on the staining intensity (0, negative; 1, weak; 2, moderate; 3, strong) and the percentage of positively stained cells (0, 0%; 1, 1%-25%; 2, 25%-50%; 3, 50%-75%; 4, 75%-100%) [21] . The final score was the product of the two scores multiplied together. The cut-off was identified as the point with the highest sum of specificity and sensitivity in the ROC curve according to a previous study [22] . The cut-offs for ANXA10 in IHCCA, PHCCA and DCCA were 5.0, 5.0 and 5.0, respectively, and the cut-offs for PLA2G4A in PHCCA and DCCA were 5.0 and 3.5, respectively.
RNA extraction and quantitative real-time PCR
Detailed in supplemental materials.
Whole-exome and mRNA sequencing
Western blotting analysis
ELISA assay
Transfection and stable cell line
CCK-8 assay
Detailed in supplemental materials
Cell cycle and apoptosis assays
Wound healing assay
Transwell assay
In vivo assay
Statistical analysis
All values are represented as the mean ± standard deviation. SPSS 17.0 and GraphPad Prism 5.0 software were used to calculate the statistical analyses and make diagrams. The correlations between ANXA10 and clinicopathological characteristics were assessed by the χ 2 or Fisher test. Survival curves were plotted using the Kaplan-Meier method, and statistical significance was compared using the log-rank test. The significant variables in univariate survival analyses were included in the final multivariable Cox proportional hazards regression model. Student's ttest was used for comparisons of two independent groups, and oneway ANOVA was used to compare multiple groups. P values b.05 were considered statistically significant. 
Results
High ANXA10 expression predicts poor prognosis in PHCCA and DCCA but not in ICCA
Potential biomarkers were first screened by exome and transcriptome sequencing with five paired frozen PHCCA tissues and adjacent normal bile duct tissues (NCBI SRA under BioProject accession PRJNA517030 and PRJNA547373). According to the sequencing results, we found that ANXA10 expression was significantly higher in PHCCA tissues than in tumor-adjacent tissues (Fig. 1a ). The mRNA levels of ANXA10 in 20 ICCA, PHCCA, DCCA tissues and their patient-paired normal tissues were detected with qRT-PCR ( Fig. 1b-d ). ANXA10 mRNA levels were remarkably higher in PHCCA and DCCA tissues than in tumor-adjacent tissues, but this tendency was not notable in ICCA tissues. Moreover, the expression of ANXA10 in another 3 pairs of PHCCA, DCCA and adjacent tissues was detected by western blotting, which also indicated the higher ANXA10 expression in PHCCA and DCCA tissues than in normal bile duct tissues ( Fig. 1e and f) .
Moreover, ANXA10 expression in a retrospective cohort comprising 91 ICCA patients, 128 PHCCA patients and 84 DCCA patients was detected with immunohistochemistry (IHC) ( Fig. 1g-i) . Interestingly, although ANXA10 is a membrane protein, the expression of ANXA10 was observed in both the nucleus and the cytoplasm. These patients were divided into low expression and high expression groups based on their IHC score for ANXA10, and the overall survival rates of patients with different ANXA10 expression were compared ( Fig. 1j-l) . In PHCCA and DCCA patients but not ICCA patients, high ANXA10 expression was remarkably associated with unfavorable prognosis, indicating that ANXA10 had different functions in PHCCA/DCCA and ICCA. Among ICCA, PHCCA and DCCA patients, PHCCA patients had the highest expression of ANXA10 ( Fig. 1m ). However, the ANXA10 level in serum was not substantially different between patients with ICCA, PHCCA, or DCCA and healthy subjects ( Fig. 1n ).
Clinical significance of ANXA10 in CCA
To determine the possible mechanism underlying ANXA10-involved CCA progression, we analyzed the correlation between ANXA10 and the clinicopathological features of PHCCA and DCCA patients. In both PHCCA and DCCA patients, higher ANXA10 expression was significantly associated with poorer differentiation ( Supplemental Table S2 ). In addition, univariate and multivariate analyses were performed to evaluate the prognostic value of ANXA10 and other clinicopathological factors (Table 1 ). In PHCCA patients, positive lymph node metastasis (P = .036, log-rank test), distant metastasis (P = .002) and advanced TNM stage (P = .001) were all significantly associated with a low overall survival rate(Supplemental Fig. S1a -S1c). In DCCA patients, lymph node metastasis (P = .019) and TNM stage (P = .019) had a strong correlation with prognosis (Supplemental Fig. S1d-1e ). Multivariate analysis with a Cox regression model was also performed to identify the independent prognostic factors of PHCCA and DCCA. Factors with a P valueb.2 were enrolled in the multivariate analysis, except for TNM stage because of its natural interaction with other factors. In both PHCCA and DCCA patients, high ANXA10 expression was confirmed as an independent prognostic factor(P = .026 in PHCCA, P = .002 in DCCA, Cox-regression hazard model). The risk of cancer-caused death in patients with high ANXA10 expression was 2.25-and 3.20-fold higher than in those with low ANXA10 expression.
ANXA10 promotes the progression of CCA cells in vitro and in vivo
Endogenous ANXA10 expression was detected in the PHCCA cell lines QBC-939 and FRH-0201, as well as in the IHCCA cell lines RBE and HCCC-9810, by qRT-PCR and western blotting ( Fig. 2a and b ). QBC-939 cells had the highest ANXA10 expression and were thus used as the cell model for RNA knockdown (Fig. 2c and d) . CCK-8 assay was applied to detect QBC939 cell proliferation and revealed that ANXA10 knockdown substantially impaired PHCCA cell proliferation ( Fig. 2e) . Cell cycle and apoptosis in QBC939 cells were detected by flow cytometry (Supplemental Fig. S2a and S2b), but there was no remarkable difference on cell cycle, apoptosis and necrosis between the scrambled and siANXA10 groups ( Fig. 2f and g, Supplemental Fig. S2c ). Wound healing and transwell assays were also performed to detect the effect of ANXA10 on cell migration ( Fig. 2h and i) . In our study, ANXA10 knockdown notably attenuated the migration and invasion of QBC939 cells. Similar results were also observed for cell invasion with the Matrigel transwell assay (Fig. 2j ). All these results indicated that ANXA10 played an essential role in the invasion and metastasis of PHCCA.
Furthermore, in vivo experiments were performed to evaluate the oncogenic function of ANXA10. First, the stable cells with ANXA10 knockdown were established via infection with a lentivirus carrying ANXA10 shRNA and verified by qRT-PCR and western blotting ( Fig. 3a  and b ). Stable cells were injected subcutaneously into BALB/c nude mice to create xenograft tumors (Fig. 3c ). Consequently, ANXA10 knockdown significantly decreased the tumor volumes ( Fig. 3d) as well as the tumor weights ( Fig. 3e ). We futher confirmed the successful Fig. S3 ). Tail vein injection with ANXA10-silenced QBC939 cells was carried out to create tumor metastatic mouse models. The weights of mice injected with shANXA10 were greater than those of mice injected with scrambled shRNA (Fig. 3f ), reflecting that ANXA10 knockdown attenuated the systemic metastasis of PHCCA. Tumor metastasis was monitored by in vivo fluorescence imaging ( Fig. 3g ) and finally confirmed with HE staining and CK19 staining( Fig. 3h and i, supplemental Fig. S4 ). In our study, ANXA10 silencing strikingly decreased the number of metastatic lesions (Fig. 3j and k) , suggesting the important role of ANXA10 in CCA metastasis.
ANXA10 expression is associated with tumor differentiation and EMT in EHCCA
As shown in Table 1 , we observed that ANXA10 expression was significantly associated with PHCCA and DCCA tumor differentiationDCCA, so we further stratified the tumors according to tumor differentiation and ANXA10 expression in PHCCA and DCCA ( Fig. 4a and b ). For both PHCCA and DCCA, poorly differentiated tumors had higher ANXA10 expression than the moderately and well-differentiated tumors ( Fig. 4c  and d) . Given that EMT is a critical event involved in tumor differentiation and metastasis, the effect of ANXA10 on EMT was measured by detecting EMT-specific proteins, including E-cadherin, Snail and Vimentin. Both qRT-PCR and western blot assays showed increased expression of E-cadherin and decreased expression of Snail and Vimentin after ANXA10 knockdown ( Fig. 4e and f ), suggesting that ANXA10 was essential for EMT in QBC939 cells.
PLA2G4A is a key molecule in ANXA10-induced EMT and metastasis
To investigate the downstream targets of ANXA10-induced metastasis of PHCCA and DCCA, transcriptome sequencing was performed (GSE132279), and several significantly altered and metastasisinvolved genes (fold changeN1.5) were selected ( Fig. 5a ). Of the altered genes, the enriched genes were clustered into several key signal transduction pathways, and the phospholipase metabolic pathway was the most significantly downregulated pathway after silencing ANXA10 (Fig. 5b) . Combined with the above results, 27 genes were chosen for further verification by qRT-PCR (Fig. 5c ). The results suggested PLA2G4A and GNA13 as possible targets of ANXA10 (fold changeN2.0). Western blotting further demonstrated that the expression of PLA2G4A but not GNA13 was regulated by ANXA10 ( Fig. 5d , Supplemental Fig. S5a and S5b). Moreover, PLA2G4A and ANXA10 also exhibited a strong correlation according to exome and transcriptome sequencing (Fig. 1a) .
The correlation between ANXA10 and PLA2G4A mRNA was evaluated in 10 cases of PHCCA and DCCA (Fig. 5e ), and PLA2G4A expression in 128 PHCCA patients and 84 DCCA patients was detected by IHC ( Fig. 5f and g) . These results suggested that PLA2G4A expression was significantly associated with ANXA10 in both PHCCA and DCCA. Additionally, the prognostic values of PLA2G4A in PHCCA and DCCA were evaluated with the Kaplan-Meier method. High PLA2G4A expression was also correlated with low overall survival rate in PHCCA and DCCA (Fig. 5h ). We combined the ANXA10 and PLA2G4A expression and evaluated the prognostic value of the co-expression of ANXA10 and PLA2G4A. Patients with the co-expression of ANXA10 and PLA2G4A seemed to have poorer prognosis than other patients, suggesting that co-expression of ANXA10 and PLA2G4A may be a more sensitive factor of EHCCA (Fig. 5i) .
The role of PLA2G4A in CCA metastasis was investigated because PLA2G4A was previously reported to promote the invasion of several types of cancer [23, 24] . A specific inhibitor of PLA2G4A, AACOCT3, was used to suppress PLA2G4A activity after ANXA10 overexpression. Consequently, ANXA10 overexpression promoted EMT (increased Snail and Vimentin and decreased E-cadherin levels) in QBC-939 cells, whereas the PLA2G4A inhibitor partially abolished these changes (Fig. 6a) . Moreover, AACOCT3 (20 μM) substantially decreased PLA2G4A-induced QBC939 cell invasion (Fig. 6b and c ), suggesting that PLA2G4A was the key effector in ANXA10-mediated invasion and metastasis. A mouse metastasis model was established with stable ANXA10-overexpressing QBC939 cells and treatment with or without AACOCF3. The weights of mice with AACOCF3 treatment were heavier than those without AACOCF3 treatment (Fig. 6d ). Metastatic lesions in the liver and lungs were monitored by an in vivo fluorescence system and confirmed with HE ( Fig. 6e and f) . AACOCF3 notably decreased the number of metastatic lesions in the liver and lungs ( Fig. 6g and h ). All these results indicated the essential role of PLA2G4A in ANXA10mediated EMT and metastasis.
ANXA10 mediates CCA metastasis by activating the PLA2G4A/PGE2/ STAT3 pathway
Considering that PGE2 is a primary product of PLA2G4A and a critical cytokine involved in inflammation and tumor metastasis [23] , the role of PGE2 in ANXA10-induced invasion and metastasis was further evaluated with in vitro and in vivo experiments. Celecoxib is a well-known specific COX-2 inhibitor that can decrease PGE2 synthesis by inhibiting COX-2. A Matrigel transwell assay revealed that celecoxib (20 μM) significantly attenuated the ANXA10-induced invasion of QBC939 cells (Fig. 7a) . In vivo experiments with mice injected with ANXA10overexpressing QBC939 cells also demonstrated that celecoxib reduced the weight loss induced by ANXA10 overexpression (Fig. 7b ) and decreased the number of metastatic lesions in the lungs and livers ( Fig. 7c and d) . All of the above results suggested that the COX-2 inhibitor celecoxib suppressed the ANXA10-induced invasion and metastasis of EHCCA.
A previous study reported that PEG2 could promote tumor cell invasion and metastasis by activating STAT3 [25] . In our study, we also demonstrated that ANXA10 knockdown decreased while ANXA10 overexpression increased the phosphorylation of STAT3 (Fig. 7e) . PGE2 is the primary product of PLA2G4A and COX-2, so exogenous PEG2 at different concentrations was used to stimulate QBC939 cells. PGE2 increased the phosphorylation of STAT3 in a time-dependent manner (Fig. 7f ). In addition, ANXA10 overexpression increased STAT3 phosphorylation, while celecoxib inhibited STAT3 phosphorylation and the EMT process in QBC939 cells, suggesting that STAT3 phosphorylation was required for ANXA10/ PLA2G4A-induced EMT and metastasis.
Discussion
Although the ANXA family members are known to have essential functions, including cell division, growth regulation, vesicle trafficking and calcium signaling, the role of the ANXA family in tumorigenesis and tumor progression is still controversial. As a new member of the ANXA family, studies on ANXA10 in cancer progression are rare and sporadic. For the first time, we screened ANXA10 by mRNA sequencing and identified it as a prognostic biomarker of PHCCA and DCCA, but not ICCA. Since CCA specimens are difficult to obtain, the cohort sample size (91 ICCA, 128 PHCCA and 84 DCCA tissues) in our study was large, and we provided remarkable statistical significance suggesting ANXA10 as a prognostic biomarker. Our results suggested that pathological detection of ANXA10 would help stratify patients with EHCCA more precisely. Patients with high ANXA10 expression are high risk and may suffer an unfavorable prognosis, which may provide important information for the individualized treatment of EHCCA. Moreover, we demonstrated that ANXA10 predicted poor prognosis in PHCCA and DCCA but not in IHCCA. This finding was also a supportive evidence of that ICCA and EHCCA had different molecular and biological features.
The physiological function of ANXA10 has not been well studied, and the underlying mechanism of how ANXA10 correlates with tumor progression is far from clear. In our study, we demonstrated for the first time that ANXA10 promoted the invasion and metastasis of EHCCA by facilitating EMT. Moreover, we suggested that ANXA10 promoted PLA2G4A expression and thus increased PGE2 generation and activated STAT3, thereby promoting EMT. These findings greatly supplement our knowledge of the oncogenic role of ANXA10 and even the whole ANXA family. Interestingly, the most well-known ANXA family member, ANXA1, was demonstrated to inhibit PLA2 activity and thereby blocking eicosanoid production 14, 15 , but we showed that ANXA10 promoted the expression of PLA2 in our study, which has not been reported about the ANXA family. Considering that the functions of ANXA family members are notably tissue-specific and context-specific, it is also possible that ANXA10 and ANXA1 exhibit different regulations of PLA2 expression and activity in different tumor types or pathological processes.
Our results demonstrated that the ANXA10-induced PLA2G4A/COX-2/PEG2/STAT3 pathway played an important role in EHCCA metastasis and indicated that blocking this pathway may be a promising therapeutic approach to treat EHCCA. In fact, the anti-tumor effects of non-steroidal anti-inflammatory drugs (NSAIDs) have attracted great attention for a long time because inflammation is a recognized hallmark of cancer that continuously contributes to the development and progression of malignancies. For example, aspirin treatment was associated with a reduction of morbidity in patients with colorectal adenoma [26, 27] , and NSAIDs were reported to improve patient survival for PIK3CA-altered head and neck cancer [28] . Regarding CCA, aspirin use was demonstrated to decrease the risk for all the three CCA subtypes [29] . The molecular mechanisms of how NSAIDs suppress tumor progression have also been widely examined in previous studies [30] . One important explanation is that NSAIDs reduce AA and PGE2 generation and therefore inhibite PGE2-induced tumor progression, which was also supported by our results. In our study, we furthermore proved that PGE2 promoted EMT and facilitated metastasis via activating STAT3 in QBC939 cells with multiple in vivo experiments. EMT is the key process of ANXA10-mediating metastasis of EHCCA since EMT makes cancer cells more aggressive, resistant to apoptosis and confers stem-like features. Moreover, EMT programs can promote the production of inflammation factors by cancer cells. In our study, the close correlation between PLA2G4A/COX-2/PGE2 and EMT in EHCCA indicated that inflammation and EMT may sustain each other in EHCCA, and that the inflammation-EMT axis plays a significant role in CCA metastasis. This should be paid more attention because longstanding inflammation is inevitable because of the bilioenteric anastomosis and bacterial influx after radical surgery for PHCCA or DCCA. In our previous study, we also demonstrated that biliary inflammation correlated with the recurrence of PHCCA by promoting HMGB1 release [6] .
Because of the low incidence and high difficulty of radical surgery, DCCAthe potential biomarkers, genetic alterations, and targeted drugs in preclinical studies or clinical trials for PHCCA and DCCA are far behind other common cancer types, such as lung cancer or colon cancer. Even IHCCA studies have made great progresses in molecular classification and genetic alteration screening, but studies of targeted therapy for PHCCA and DCCA have remained stagnant in recent years. Our results indicated that PLA2G4A and its downstream targets COX-2, PGE2 and STAT3 can all be regarded as potential drug targets for PHCCA and DCCA. PLA2G4A, COX-2, and PGE2 have all been demonstrated to be involved in the progression and prognosis of many types of cancers, including breast cancer, ovarian cancer and hepatocellular carcinoma [31] [32] [33] . COX-2 is a potential drug target for several types of cancers, and COX-2 inhibitors are extensively used to treat inflammation and exhibit anti-tumor effect in numerous studies. Our results demonstrated that PLA2G4A and downstream PGE2 promoted the metastasis of EHCCA via facilitating EMT, and indicated that inhibitors of PLA2G4A and COX-2 suppressed ANXA10-induced metastasis. These results revealed new molecular mechanism of EHCCA metastasis and provided new insights into precise treatment of PHCCA and DCCA. Our findings pointed the potency of NSAIDs as promising drug to suppress metastasis of PHCCA and DCCA.
In conclusion, we first demonstrated that ANXA10 is an independent prognostic biomarker of PHCCA and DCCA. After various in vitro and in vivo experiments, we suggested that PLA2G4A expression was regulated by ANXA10 and that it is essential for ANXA10-induced proliferation, invasion and EMT in CCA. PGE2 generation and STAT3 activation downstream of PLA2G4A led to ANXA10-mediated EMT facilitation and tumor metastasis. Our results may help stratify high-risk patients with PHCCA and DCCA and guide individualized treatment for PHCCA and DCCA. ANXA10, PLA2G4A and COX-2 are potential drug targets for PHCCA and DCCA, and blocking the ANXA10/PLA2G4A/PGE2 pathway is a promising therapeutic approach for CCA treatment. The association between relative PLA2G4A and ANXA10 mRNA levels in 10 PHCCA and DCCA fresh tissue samples was analyzed according to the Pearson-correlation factor. (f-g) PHCCA and DCCA patients with high ANXA10 expression also had high PLA2G4A expression. Left: Representative IHC images of ANXA10 expression in PHCCA (f) and DCCA (g). Scale bar: 50 μm. Right: IHC score of PLA2G4A for PHCCA (f) and DCCA (g) patients with low or high ANXA10 expression. Statistical significance between groups was assessed using Student's t-test. * represents p b .05. (h) Overall survival curves for patients with PHCCA and DCCA were stratified according to PLA2G4A expression. (i) Overall survival curves for patients with PHCCA and DCCA were stratified according to patients with co-expression of ANXA10 and PLA2G4A, and other patients. 
